Boundless Bio, Inc. (BOLD)

Boundless Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-61.76	-65.36	-49.43	-45.9	-25.21
Depreciation & Amortization	1.24	1.09	0.96	0.94	0.68
Loss (Gain) From Sale of Investments	-3.14	-5.06	-3.3	0.5	0.54
Stock-Based Compensation	6.8	7.52	3.34	2.29	1.16
Other Operating Activities	3.23	2.65	2.39	1.7	0.42
Change in Accounts Payable	-1.39	0.78	1.66	1.91	1.22
Change in Other Net Operating Assets	2.89	-2.45	-2.46	-1.05	-2.06
Operating Cash Flow	-52.12	-60.84	-46.86	-39.6	-23.25
Capital Expenditures	-0.59	-2.54	-0.63	-1.07	-2.03
Investment in Securities	27.24	-23.57	-37.63	17.2	-57.25
Investing Cash Flow	26.65	-26.1	-38.26	16.13	-59.29
Issuance of Common Stock	0.23	93.17	0.18	0.13	0.21
Other Financing Activities	-	-3.35	-1.96	-	-
Financing Cash Flow	0.23	89.82	97.9	0.13	105.53
Net Cash Flow	-25.23	2.88	12.78	-23.34	22.99
Free Cash Flow	-52.71	-63.38	-47.49	-40.66	-25.28
Free Cash Flow Per Share	-2.36	-3.73	-39.05	-37.04	-29.38
Levered Free Cash Flow	-35.31	-37.58	-30.95	-24.76	-
Unlevered Free Cash Flow	-35.31	-37.58	-30.95	-24.76	-
Change in Working Capital	1.51	-1.68	-0.8	0.87	-0.84

Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q